A phase I study of intracarotid artery infusion of cis-diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors

D. J. Stewart, S. Wallace, Lynn G Feun, M. Leavens, S. E. Young, S. Handel, G. Mavligit, R. S. Benjamin

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

A Phase I study of intracarotid cis-diamminedichloroplatinum was performed in 11 patients with intracerebral tumors (five glioblastoma, four melanoma, one meningeal sarcoma, and one lung carcinoma) progressing after radiation ± chemotherapy. The internal carotid artery was temporarily cannulated by a percutaneous transfemoral approach. All patients received i.v. heparin, mannitol, and fluids; seven received dexamethasone, 50 mg i.v. twice the day before and the day of treatment. Intracarotid cis-diamminedichloroplatinum, 60 to 100 mg/sq m in 175 to 250 ml 0.45% NaCl solution with 1000 units heparin, was infused over 1 hr. Six patients received two or more courses (maximum of 6) at 2- to 8-week intervals. Gastrointestinal toxicity was mild to moderate. Ototoxicity was minor. Central nervous system (CNS) toxicity was focal, severe, permanent, and possibly due to embolus in one patient at 75 mg/sq m; focal and reversible in one patient at 100 mg/sq m; and generalized but reversible in one patient at 75 mg/sq m. Possible CNS toxicity was noted in two additional patients. Two patients with CNS toxicity developed permanent ipsilateral retinal toxicity, and one patient without CNS toxicity developed bilateral decreased visual and auditory acuity 2 weeks after his sixth treatment. Renal and hematological toxicity and orbital pain were mild. Response status included: early death, one; probable responses, six (2+, 4+, 6, 6+, 8, and 8+ months); stabilization, two (3+ and 4 months); and failure, two. We recommend cis-diamminedichloroplatinum (60 mg/sq m)every 2 to 4 weeks for Phase II studies. Severe CNS and retinal toxicity are possible.

Original languageEnglish
Pages (from-to)2059-2062
Number of pages4
JournalCancer Research
Volume42
Issue number5
StatePublished - Jul 13 1982
Externally publishedYes

Fingerprint

Cisplatin
Arteries
Central Nervous System
Neoplasms
Heparin
Internal Carotid Artery
Mannitol
Glioblastoma
Embolism
Sarcoma
Dexamethasone
Visual Acuity
Melanoma
Radiation
Carcinoma
Kidney
Drug Therapy
Pain
Lung
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Stewart, D. J., Wallace, S., Feun, L. G., Leavens, M., Young, S. E., Handel, S., ... Benjamin, R. S. (1982). A phase I study of intracarotid artery infusion of cis-diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors. Cancer Research, 42(5), 2059-2062.

A phase I study of intracarotid artery infusion of cis-diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors. / Stewart, D. J.; Wallace, S.; Feun, Lynn G; Leavens, M.; Young, S. E.; Handel, S.; Mavligit, G.; Benjamin, R. S.

In: Cancer Research, Vol. 42, No. 5, 13.07.1982, p. 2059-2062.

Research output: Contribution to journalArticle

Stewart, DJ, Wallace, S, Feun, LG, Leavens, M, Young, SE, Handel, S, Mavligit, G & Benjamin, RS 1982, 'A phase I study of intracarotid artery infusion of cis-diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors', Cancer Research, vol. 42, no. 5, pp. 2059-2062.
Stewart, D. J. ; Wallace, S. ; Feun, Lynn G ; Leavens, M. ; Young, S. E. ; Handel, S. ; Mavligit, G. ; Benjamin, R. S. / A phase I study of intracarotid artery infusion of cis-diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors. In: Cancer Research. 1982 ; Vol. 42, No. 5. pp. 2059-2062.
@article{253e1fd67fd64af38a780a3eb9ed96d5,
title = "A phase I study of intracarotid artery infusion of cis-diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors",
abstract = "A Phase I study of intracarotid cis-diamminedichloroplatinum was performed in 11 patients with intracerebral tumors (five glioblastoma, four melanoma, one meningeal sarcoma, and one lung carcinoma) progressing after radiation ± chemotherapy. The internal carotid artery was temporarily cannulated by a percutaneous transfemoral approach. All patients received i.v. heparin, mannitol, and fluids; seven received dexamethasone, 50 mg i.v. twice the day before and the day of treatment. Intracarotid cis-diamminedichloroplatinum, 60 to 100 mg/sq m in 175 to 250 ml 0.45{\%} NaCl solution with 1000 units heparin, was infused over 1 hr. Six patients received two or more courses (maximum of 6) at 2- to 8-week intervals. Gastrointestinal toxicity was mild to moderate. Ototoxicity was minor. Central nervous system (CNS) toxicity was focal, severe, permanent, and possibly due to embolus in one patient at 75 mg/sq m; focal and reversible in one patient at 100 mg/sq m; and generalized but reversible in one patient at 75 mg/sq m. Possible CNS toxicity was noted in two additional patients. Two patients with CNS toxicity developed permanent ipsilateral retinal toxicity, and one patient without CNS toxicity developed bilateral decreased visual and auditory acuity 2 weeks after his sixth treatment. Renal and hematological toxicity and orbital pain were mild. Response status included: early death, one; probable responses, six (2+, 4+, 6, 6+, 8, and 8+ months); stabilization, two (3+ and 4 months); and failure, two. We recommend cis-diamminedichloroplatinum (60 mg/sq m)every 2 to 4 weeks for Phase II studies. Severe CNS and retinal toxicity are possible.",
author = "Stewart, {D. J.} and S. Wallace and Feun, {Lynn G} and M. Leavens and Young, {S. E.} and S. Handel and G. Mavligit and Benjamin, {R. S.}",
year = "1982",
month = "7",
day = "13",
language = "English",
volume = "42",
pages = "2059--2062",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - A phase I study of intracarotid artery infusion of cis-diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors

AU - Stewart, D. J.

AU - Wallace, S.

AU - Feun, Lynn G

AU - Leavens, M.

AU - Young, S. E.

AU - Handel, S.

AU - Mavligit, G.

AU - Benjamin, R. S.

PY - 1982/7/13

Y1 - 1982/7/13

N2 - A Phase I study of intracarotid cis-diamminedichloroplatinum was performed in 11 patients with intracerebral tumors (five glioblastoma, four melanoma, one meningeal sarcoma, and one lung carcinoma) progressing after radiation ± chemotherapy. The internal carotid artery was temporarily cannulated by a percutaneous transfemoral approach. All patients received i.v. heparin, mannitol, and fluids; seven received dexamethasone, 50 mg i.v. twice the day before and the day of treatment. Intracarotid cis-diamminedichloroplatinum, 60 to 100 mg/sq m in 175 to 250 ml 0.45% NaCl solution with 1000 units heparin, was infused over 1 hr. Six patients received two or more courses (maximum of 6) at 2- to 8-week intervals. Gastrointestinal toxicity was mild to moderate. Ototoxicity was minor. Central nervous system (CNS) toxicity was focal, severe, permanent, and possibly due to embolus in one patient at 75 mg/sq m; focal and reversible in one patient at 100 mg/sq m; and generalized but reversible in one patient at 75 mg/sq m. Possible CNS toxicity was noted in two additional patients. Two patients with CNS toxicity developed permanent ipsilateral retinal toxicity, and one patient without CNS toxicity developed bilateral decreased visual and auditory acuity 2 weeks after his sixth treatment. Renal and hematological toxicity and orbital pain were mild. Response status included: early death, one; probable responses, six (2+, 4+, 6, 6+, 8, and 8+ months); stabilization, two (3+ and 4 months); and failure, two. We recommend cis-diamminedichloroplatinum (60 mg/sq m)every 2 to 4 weeks for Phase II studies. Severe CNS and retinal toxicity are possible.

AB - A Phase I study of intracarotid cis-diamminedichloroplatinum was performed in 11 patients with intracerebral tumors (five glioblastoma, four melanoma, one meningeal sarcoma, and one lung carcinoma) progressing after radiation ± chemotherapy. The internal carotid artery was temporarily cannulated by a percutaneous transfemoral approach. All patients received i.v. heparin, mannitol, and fluids; seven received dexamethasone, 50 mg i.v. twice the day before and the day of treatment. Intracarotid cis-diamminedichloroplatinum, 60 to 100 mg/sq m in 175 to 250 ml 0.45% NaCl solution with 1000 units heparin, was infused over 1 hr. Six patients received two or more courses (maximum of 6) at 2- to 8-week intervals. Gastrointestinal toxicity was mild to moderate. Ototoxicity was minor. Central nervous system (CNS) toxicity was focal, severe, permanent, and possibly due to embolus in one patient at 75 mg/sq m; focal and reversible in one patient at 100 mg/sq m; and generalized but reversible in one patient at 75 mg/sq m. Possible CNS toxicity was noted in two additional patients. Two patients with CNS toxicity developed permanent ipsilateral retinal toxicity, and one patient without CNS toxicity developed bilateral decreased visual and auditory acuity 2 weeks after his sixth treatment. Renal and hematological toxicity and orbital pain were mild. Response status included: early death, one; probable responses, six (2+, 4+, 6, 6+, 8, and 8+ months); stabilization, two (3+ and 4 months); and failure, two. We recommend cis-diamminedichloroplatinum (60 mg/sq m)every 2 to 4 weeks for Phase II studies. Severe CNS and retinal toxicity are possible.

UR - http://www.scopus.com/inward/record.url?scp=0020075598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020075598&partnerID=8YFLogxK

M3 - Article

C2 - 7199971

AN - SCOPUS:0020075598

VL - 42

SP - 2059

EP - 2062

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 5

ER -